The 20 Best Bladder Cancer Doctors Near Me in Rosedale, MD

Dr. Max Kates is the R. Christian B. Evensen Professor and an associate professor of urology and oncology at the Brady Urological Institute at Johns Hopkins. He also directs the Division of Urologic Oncology for the Brady Urological Institute. Dr. Kates completed his undergraduate degree at Wesleyan University in Connecticut before pursuing his medical degree at Mount Sinai School of Medicine in New York. He then went on to train at Johns Hopkins for his urologic residency and Society of Urologic Oncology (SUO) fellowship. Dr. Kates has expertise in all areas of urologic oncology, with a particular emphasis on bladder and prostate cancer. With training in open, endoscopic, and robotic surgical approaches, Dr. Kates’ surgical philosophy is to assess the unique needs of each patient, and develop the right treatment plan for their malignancy. He is very hands on in his approach in the clinic and the operating room, and believes open communication with the patient, the patient’s family, and referring providers is key to ensuring a speedy recovery. As the clinical director of the bladder cancer multidisciplinary clinic, Dr. Kates works with the team at the Johns Hopkins Greenberg Bladder Cancer Institute to deliver a personalized approach to bladder cancer utilizing cutting edge precision medicine approaches. Dr. Kates’ research interests involve novel treatments for cancers of the urinary tract. Dr. Kates has authored more than 135 journal articles in the fields of bladder, prostate, and kidney cancer. He currently has a provisional patent for a novel intravesical chemotherapy developed with nano-engineer collaborators. Additionally, Dr. Kates has made important discoveries into the mechanism of action of intravesical BCG, the most common treatment for bladder cancer. He is the principal investigator on multiple trials, and is currently leading EA8212 BRIDGE, which is a randomized trial open in over 150 centers in the United States comparing BCG to GemDoce chemotherapy for early stage bladder cancer. To inquire about an appointment or make a referral, Dr. Kates can be contacted by phone (410) 614-0009. Dr. Kates is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy.

Dr. Noah Hahn is a medical oncologist in the Baltimore area, caring for patients with bladder cancer. He serves as the deputy director of the Greenberg Bladder Cancer Institute at the Johns Hopkins School of Medicine. Dr. Hahn earned his M.D. from Indiana University School of Medicine. He completed his residency in internal medicine at Duke University School of Medicine and performed a fellowship in medical oncology at Indiana University School of Medicine. Dr. Hahn joined the Johns Hopkins faculty in 2014. Prior to joining Johns Hopkins, Dr. Hahn was the director of the Genitourinary Medical Oncology Program at Indiana University and chief scientific officer for the Hoosier Oncology Group, a cancer research organization that evaluates innovative and promising approaches to cancer treatment. He is currently conducting clinical trials to test new therapies for bladder cancer, including those for early stage bladder cancer. Dr. Hahn is a member of the Bladder Cancer Task Force for the National Cancer Institute’s Genitourinary Cancer Steering Committee and is chair of the Bladder Cancer Subcommittee of the Eastern Cooperative Oncology Group. Dr. Hahn is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Nephrectomy.

Dr. Jean Hoffman-Censits is a genitourinary cancer specialist in Baltimore, caring for patients with urothelial cancers of the bladder and upper tract. She serves as co-leader of the Women’s Bladder Cancer Program in the Greenberg Bladder Cancer Institute at the Johns Hopkins University School of Medicine. Dr. Hoffman-Censits received her undergraduate degree in neuroscience from Trinity College. She earned her M.D. degree from the Sidney Kimmel Medical College of Thomas Jefferson University. She completed her residency at Thomas Jefferson University Hospital and performed a fellowship in hematology and oncology at Temple University Medical Center. She joined the Johns Hopkins faculty in 2018. Dr. Hoffman-Censits's research interests focus on urothelial cancers. Her clinical research has helped identify urothelial cancer sub-types and establish new treatments for bladder and upper tract urothelial cancers. She is a member of the American Medical Association, the American Society of Clinical Oncology, the American Urological Association and the Society for Immunotherapy of Cancer. Dr. Hoffman is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. Her top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Bladder Reconstruction, and Nephrectomy.

Dr. Edward Wright is an associate professor of urology at the Johns Hopkins School of Medicine. He serves as the Director of Urology at the Johns Hopkins Bayview Medical Center. His clinical and research interests are in male and female urinary incontinence, complex voiding dysfunction and pelvic genitourinary reconstructive surgery. His specialty has less to do with surgical removal and more with mending urological body parts and restoring functionality in them. His passion for Johns Hopkins lies in the fact that it is the type of place where things can be done, and patients’ questions can be answered and solutions to their problems can be found through all of the resources Johns Hopkins has to offer. Dr. Wright earned his M.D. from Dartmouth Medical School in New Hampshire. He completed his residency in urology at The Presbyterian Hospital in the City of New York and performed a fellowship in Urogynecology at Duke University School of Medicine. Dr. Wright is a member of the American Urologic Association and the Mid-Atlantic Section of American Urologic Association as well as the Society for Urodynamics and Female Urology. He has been recognized with a number of awards including Winner of the Urology Chief Resident's debate New York section of the American Urologic Society at the The New York Academy of Medicine. Dr. Wright is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Stress Urinary Incontinence, Urinary Incontinence, Neurogenic Bladder, Osteotomy, and Ureteroscopy.

Dr. Marisa Clifton is the Director of Women’s Health at the Brady Urological Institute. She is fellowship trained. As a leader in the field of female urology, her clinical expertise includes surgical and nonsurgical treatment of pelvic organ prolapse, stress urinary incontinence, urgency urinary incontinence, urinary fistulas, genitourinary reconstruction and urethral diverticula. Dr. Clifton is also an Assistant Professor of Urology at the Johns Hopkins School of Medicine and serves as the Director of Robotic Education. In addition, she serves as Vice President of Medical Affairs at Johns Hopkins Bayview Medical Center. She also serves as Associate Chief Medical Officer of The Johns Hopkins Hospital. Her research interests include medical education and clinical outcomes after surgery. Dr. Clifton received her medical degree from the Johns Hopkins University School of Medicine and completed her residency in urology at the Mayo Clinic in Rochester, Minnesota. She completed her fellowship in Female Pelvic Medicine and Reconstructive Surgery at The Cleveland Clinic in Cleveland, Ohio. Dr. Clifton is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. Her top areas of expertise are Urinary Incontinence, Obstructive Uropathy, Neurogenic Bladder, Sacral Nerve Stimulation, and Hormone Replacement Therapy (HRT).

Dr. Andrew J. Cohen is an Associate Professor of Urology at Johns Hopkins. He serves as the Division Director of Benign Urology and Director of Advanced Practice Providers at the Johns Hopkins Brady Urological Institute. He has a robust clinical practice focusing on complex genitourinary reconstruction. In particular, he has interest in the management of erectile dysfunction, urinary incontinence, stricture diseases of the urinary system, peyronie's disease, genital skin conditions, buried penis, urinary diversion, and other benign urologic conditions. He has extensive experience in robotic surgery. He also focuses on issues pertinent to cancer survivorship in men. He is well equipped to perform novel minimally invasive procedures such as endoscopic urethroplasty and robotic buccal ureteroplasty. He has an extensive research portfolio, with particular concentration in outcomes and safety research. Dr. Cohen received dual B.S. degrees summa cum laude from the University of Florida in Chemistry and Chemical Engineering, followed by an MD from the University of Chicago where he was inducted into the Alpha Omega Alpha Honor Society. His urologic training was pursued at the University of Chicago. Furthermore, he completed a fellowship in Genitourinary Reconstruction and Trauma at the University of California, San Francisco. Among many honors, he was invited to join the Trauma and Urologic Reconstructive Network of Surgeons in 2025. He was a also a recipient of the 'Rising Star' Award from the Society of Genitouinary Reconstructive Surgeons in 2025. Dr. Cohen is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Urethral Stricture, Hydronephrosis, Obstructive Uropathy, Prostatectomy, and Lithotripsy.

Soum Lokeshwar is a Urologist in Baltimore, Maryland. Dr. Lokeshwar is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Bladder Cancer, Retrograde Ejaculation, Prostate Cancer, Prostatectomy, and Aquablation.

Dr. Civelek is a professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. He serves as the director of the Nuclear Medicine Residency Program. Dr. Civelek earned his medical degree at Istanbul University, Istanbul School of Medicine, and completed his residency at Hacettepe University Medical Center, Ankara. He received a scholarship from the International Atomic Energy Agency when he completed his nuclear medicine residency and fellowship at Johns Hopkins in the Division of Nuclear Medicine. After his period as a postdoctoral fellow, he joined Johns Hopkins Medicine as full-time faculty until 2003. In his early years at Johns Hopkins, Dr. Civelek assisted the clinical and research programs. He later served as director of nuclear cardiology and clinical director, the director of Nuclear Medicine Residency Program, as well as medical director of the Nuclear Medicine Technologist Program. Prior to his return to Johns Hopkins, Dr. Civelek was a professor and director of nuclear medicine and PET at the University of Louisville and a professor and director of nuclear medicine at the Saint Louis University Hospital. Dr. Civelek spent two years in the body MRI and MRI-PET section, Department of Radiology and Imaging Sciences, at National Institutes of Health Clinical Center before serving as the deputy chief in their nuclear medicine section. He is a fellow of the American College of Nuclear Medicine and The American College of Angiology, and is a fellow and founding member of the American Society of Nuclear Cardiology. Dr. Civelek has trained numerous American and international physicians in nuclear medicine, including nuclear cardiology and nuclear oncology. He has a worldwide reputation in nuclear medicine and lectures at medical centers in the U.S. and internationally on nuclear medicine, including nuclear cardiology and nuclear oncology/PET-CT and PET-MRI. Dr. Civelek is committed to the continued progress of nuclear medicine, cardiology and oncology and the development of new tumor-targeting radiopharmaceuticals for imaging and therapy. He supports high quality clinical trials and patient care and safety. To date, Dr. Civelek has published more than 210 peer-reviewed manuscripts and abstracts, and he has participated in and fostered many nuclear oncology research projects. He has served on the editorial boards of several journals. He is a reviewer for multiple scientific journals, including the Journal of Nuclear Medicine, American Journal of Radiology, and Journal of Urology. Dr. Civelek is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Neuroendocrine Tumor, Prostate Cancer, Lung Cancer, and Familial Prostate Cancer.

Dr. Nilofer S. Azad is Professor of Oncology at Johns Hopkins University School of Medicine and serves as the Associate Cancer Center Director for Clinical Research for the Johns Hopkins Sidney Kimmel Cancer Center. Dr. Azad earned her medical degree and completed a residency in internal medicine at Baylor College of Medicine in Houston, Texas. She then completed a fellowship in oncology and hematology at the National Institute of Health's National Cancer Institute in Bethesda, Maryland where she served as chief fellow. Dr. Azad’s research focused on early phase drug development and the intersection of moving exciting laboratory findings into patients for new treatment options Dr. Azad joined the faculty at the Kimmel Cancer Center in 2008. Dr. Azad’s clinical expertise is in cancers of the gastrointestinal tract, with a concentration in colorectal cancer, cholangiocarcinoma and pancreaticobiliary tract cancer. Her research efforts are dedicated to developing new drug combinations for patients with advanced cancer. In particular, Dr. Azad’s laboratory and clinical trials explore epigenetic therapy in combination with chemotherapy and immunotherapy to improve survival for patients, as well as molecularly targeted drugs. She is an active clinical trialist, leading multiple clinical trials of molecularly targeted agents for advanced cancer patients. Dr. Azad has received numerous grants for her work from entities such as the NCI (National Cancer Center), American Cancer Society, American Society of Clinical Research, Breakthrough Cancer Foundation, the Lustgarten Foundation, The Gateway Foundation, and the National Comprehensive Cancer Network, among others. She served as Principal for Johns Hopkins on the AACR Stand Up 2 Cancer Colorectal Cancer Dream Team and is a member of the Stand Up 2 Cancer Epigenetics Dream Team, leading the GI cancer initiatives for the group. Dr. Azad is a national leader in GI cancer, including serving as a member of the national NCI Colon Cancer Task Force and as Co-Chair of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. She has a presidential appointment to the National Cancer Advisory Board. Dr. Azad is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. Her top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, Pancreatic Cancer, Hepato-Pancreato-Biliary Surgery, and Colonoscopy.

Sunil H. Patel, M.D., M.A., is an Assistant Professor of Urology and Oncology at the School of Medicine at Johns Hopkins. He serves as and the Director of the Urologic Oncology Fellowship. He also serves as Director of the Testicular Cancer program. He treats all urologic malignancies, including adrenal cancer, kidney cancer, urothelial cancer, bladder cancer, prostate cancer, testes cancer, and penile cancers. Additionally, he has advanced training in complex robotic and open surgical cases. His clinical and research focus is in Urologic Oncology, with areas of focus in bladder cancer, testes cancer, and kidney cancer. Dr. Patel completed his undergraduate studies at California Polytechnic State University, San Luis Obispo where he studied Biological Sciences. He completed his Masters at Boston University, completing his thesis on microfluidics, afterwards completing his medical degree at Boston University. He completed his general surgery internship and urology residency at University of California, San Diego. He continued his training through a Society of Urologic Oncology Fellowship in urologic oncology at the Johns Hopkins Hospital. He joined Johns Hopkins in June 2020 with interests in environmental factors contributing to oncogenesis in urological cancers, especially bladder cancer. He is dedicated to international health and works closely with international volunteers in urology and has done several mission trips and guest lectures. Dr. Patel is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery.

Dr. Kenneth Pienta is the Donald S. Coffey Professor of Urology and a professor of oncology at the Johns Hopkins School of Medicine. He also holds an appointment in the department of pharmacology and molecular sciences. He is an internationally recognized leader in prostate cancer research and translational science. Dr. Pienta serves as the director of research for the Brady Urological Institute and co-leader of the Kimmel Cancer Center's Prostate Cancer Program. Dr. Pienta has a proven, peer-reviewed track record in organizing and administering a translational research program that successfully incorporates bench research, agent development and clinical application. He has international expertise in the development of novel chemotherapeutic programs for prostate cancer and has championed the concept that translational research is often best accomplished by multi-disciplinary teams of scientists and clinicians. Under his direction, the success of these endeavors led to the receipt of the first annual American Association for Cancer Research Team Science Award in 2007. Dr. Pienta received his B.A. in human biology from the Johns Hopkins University. He earned his M.D. from the Johns Hopkins School of Medicine. He completed his residency at the University of Chicago Hospitals and Clinics and performed a fellowship in oncology at The Johns Hopkins Hospital. Prior to joining Johns Hopkins, Dr. Pienta was the associate vice president for research, health sciences for the University of the Michigan from 2012 to 2013 and director of precision medicine for the Michigan Center for Translational Pathology from 2008 to 2013. He joined the Johns Hopkins faculty in 2013. Dr. Pienta's research interests include the ecology of cancer, tumor microenvironment, metastasis, biomarker development and novel therapeutic development. Dr. Pienta is a two-time American Cancer Society Clinical Research Professor Award recipient. He holds several patents, has authored more than 350 peer-reviewed articles and has been the principle investigator on numerous local and national clinical trials. Dr. Pienta is currently actively developing clinical trials and treating patients with newly diagnosed high risk and metastatic prostate cancer. Dr. Pienta is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Prostate Cancer, Bone Tumor, Familial Prostate Cancer, Prostatectomy, and Orchiectomy.

Peter Filderman is a Urologist in Baltimore, Maryland. Dr. Filderman is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Enlarged Prostate (BPH), UPJ Obstruction, Urinary Tract Infection in Children, Ureteroscopy, and Bladder Reconstruction.

Nirmish Singla is an Oncologist in Lutherville, Maryland. Dr. Singla is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Renal Cell Carcinoma (RCC), Urothelial Cancer, Nephrectomy, and Orchiectomy.

William Dowling is a Urologist in Rosedale, Maryland. Dr. Dowling is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Familial Prostate Cancer, Prostate Cancer, Enlarged Prostate (BPH), UPJ Obstruction, and Ureteroscopy.

Ryan Cleary is a Urologist in Baltimore, Maryland. Dr. Cleary is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Ureterocele, Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Reconstructive Urology Surgery, and Nephrectomy.

Jayant Uberoi is a Urologist in Rosedale, Maryland. Dr. Uberoi is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Horseshoe Kidney, UPJ Obstruction, Enlarged Prostate (BPH), Ureteroscopy, and Prostatectomy.

Kannan Manickam is a Urologist in Rosedale, Maryland. Dr. Manickam is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Urinary Incontinence, UPJ Obstruction, Enlarged Prostate (BPH), Urinary Tract Infection in Children, and Ureteroscopy.

Anup Shah is a Urologist in Baltimore, Maryland. Dr. Shah is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Kidney Stones, Perirenal Abscess, Carbuncle, Lithotripsy, and Ureteroscopy.

Michael Rezaee is a Urologist in Baltimore, Maryland. Dr. Rezaee is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Bladder Cancer, Erectile Dysfunction (ED), Malakoplakia, Cystectomy, and Lithotripsy.

Brad Lerner is a Urologist in Baltimore, Maryland. Dr. Lerner is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Enlarged Prostate (BPH), Familial Prostate Cancer, Prostate Cancer, Ureteroscopy, and Prostatectomy.